Breast cancer risk assessment for possible tailored screening for Japanese women
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Accurate risk assessment for individual women is essential for effective screening of breast cancer (BC) in Japan, because the incidence of BC is still lower than in Western countries. We investigated various new risk factors of BC by means of case control studies and found that serum estrone and adiponectine levels as well as mammographic breast density were significantly correlated to BC risk. Combining these new factors and conventional risk factors of BC may result in a new and useful risk assessment tool, may improve the cost-effectiveness of screening, and may enable us to reduce the BC mortality of Japanese women.
- Quinn M, Allen E. Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. United Kingdom Association of Cancer Registries. BMJ. 1995;311:1391–5.
- Cronin KA, Feuer EJ, Clarke LD, Plevritis SK. Impact of adjuvant therapy and mammography on US mortality from 1975 to 2000: comparison of mortality results from the CISNET breast cancer base case analysis. J Natl Cancer Inst. 2006;36:112–21.
- Coldman A, Phillips N, Warren L, Kan L. Breast cancer mortality after screening mammography in British Columbia women. Int J Cancer. 2007;120:1076–80. CrossRef
- Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335:1134. CrossRef
- Ahn J, Schatzkin A, Lacey JV Jr, Albanes D, Ballard-Barbash R, Adams KF, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007;167:2091–102. CrossRef
- Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78. CrossRef
- Cuzick J. Hormone replacement therapy and the risk of breast cancer. Eur J Cancer. 2008;44:2344–9. CrossRef
- Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2008;17:3150–60. CrossRef
- Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.
- Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen versus raloxifene on the risk of development breast cancer and other disease outcomes: the NSABP study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41. CrossRef
- Miyoshi Y, Tanji Y, Taguchi T, Tamaki Y, Noguchi S. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. Clin Cancer Res. 2003;9:2229–33.
- Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrine Metab. 2001;86:3815–9. CrossRef
- Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29–33. CrossRef
- Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;9:5699–704.
- Dos Santos E, Benaitreau D, Diedonne MN, Leneveu MC, Serazin V, Giudicelli Y, et al. Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep. 2008;20:971–7.
- Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP. Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer. 2008;98:370–9. CrossRef
- Wolfe JN. Breast patterns as index of risk of breast cancer. Am J Roentgenol. 1976;126:1130–9.
- Wolfe JN, Saftlas AF, Salane M. Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case–control study. Am J Roentgenol. 1987;148:1087–92.
- Saftlas AF, Hoover RN, Brinton LA, Szkio M, Olson DR, Salane M, et al. Mammographic densities and risk of breast cancer. Cancer. 1991;67:2883–8. CrossRef
- Boyed NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 1995;87:670–5. CrossRef
- Nagao Y, Kawaguchi Y, Sugiyama Y, Saji S, Kashiki Y. Relationship between mammographic density and the risk of breast cancer in Japanese women: a case–control study. Breast Cancer. 2003;10:228–33. CrossRef
- Nagata C, Matsubara T, Fujita H, Nagao Y, Shibuya C, Kashiki Y, et al. Mammographic density and the risk of breast cancer in Japanese women. Br J Cancer. 2005;92:2102–6. CrossRef
- Kotsuma Y, Tamaki Y, Nishimura T, Tsubai M, Ueda S, Shimazu K, et al. Quantitative assessment of mammographic density and breast cancer risk for Japanese women. Breast. 2008;17:27–35. CrossRef
- Gabe R, Duffy SW. Evaluation of service screening mammography in practice: the impact on breast cancer mortality. Ann Oncol. 2005;16(Suppl 2):ii153–62. CrossRef
- Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86. CrossRef
- Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Yamamura J, Irahara N, et al. Association of genetic polymorphism in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur J Cancer. 2003;39:2531–7. CrossRef
- Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett. 2004;210:197–203. CrossRef
- Ishitobi M, Miyoshi Y, Ando A, Hasegawa S, Egawa C, Tamaki Y, et al. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis. Clin Cancer Res. 2003;9:1376–80.
- Randall D, Morrell S, Taylor R, Hung WT. Annual or biennial mammography screening for women at a higher risk with a family history of breast cancer: prognostic indicators of screen-detected cancers in New South Wales, Australia. Cancer Causes Control, 2008 (Epub ahead of print).
- White E, Miqlioretti DL, Yankaskas BC, Rosenberg RD, Kerlikowske K, Saba L, et al. Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl Cancer Inst. 2004;96:1832–9. CrossRef
- The Breast Screening Frequency Trial Group. The frequency of breast cancer screening: results from the UKCCR randomized trial. Eur J Cancer. 2002;38:1458–64. CrossRef
- Berg WA. Tailored supplemental screening for breast cancer: what now and what next? Am J Roentogenol. 2009;192:390–9. CrossRef
- Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society Guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89. CrossRef
- Breast cancer risk assessment for possible tailored screening for Japanese women
Volume 16, Issue 4 , pp 243-247
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Breast cancer screening
- Risk factor
- Industry Sectors
- Author Affiliations
- 1. Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamadaoka, Suita, Osaka, 565-0871, Japan
- 2. Department of Breast and Endocrine Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan